Shingles vaccine study for adults 50 and older
Treatments studied
Part of Infections clinical trials.
This study tests a new vaccine to prevent shingles (a painful rash condition) in adults 50 and older. It checks how safe the vaccine is and how well it triggers the body's immune defense.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years of age or older and in good general health.
- You must be willing to use birth control for 3 months after the last shot if you or your partner can get pregnant.
- You cannot have had shingles before.
- You cannot have received a chickenpox or shingles vaccine in the past.
- You cannot be taking medications that weaken the immune system, such as steroids or immunosuppressants.
- You cannot have hepatitis B, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.
This trial tests an experimental vaccine designed to prevent shingles (a painful rash caused by the varicella-zoster virus). It will help see if the vaccine is safe and triggers a good immune response in adults 40 and older.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This study tests an investigational vaccine (SYS6017) to see how well it works and if it's safe for adults 40 and older. The vaccine aims to prevent shingles, a painful rash caused by the same virus as chickenpox.
This trial is testing an experimental mRNA vaccine for preventing shingles. It aims to see if the vaccine is safe and triggers a good immune response in people aged 50 to 79.
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.